CeQur Simplicity

The convenient, discreet, 3-day, wearable insulin Patch for injection-free dosing

Mealtime Insulin is Always within Reach

CeQur Simplicity

  • Use is clinically shown to reduce A1C and increase time-in-range1,2
  • Easy to teach, learn, and use1,3
  • Preferred by patients and professionals1

Mealtime insulin is always within reach

CeQur Simplicity Device

Simplify Mealtime Insulin With A Click

CeQur Simplicity™ removes known barriers to mealtime dosing,4 such as inconvenience, embarrassment, and injection pain.

conveniently worn


  • Fits into the lives of people requiring mealtime insulin dosing
  • Wearable while showering, sleeping, exercising, and swimming5
  • Easy to use
discreet dosing


  • Worn and dosed under clothing
  • Compact design
  • Small (65x36 mm), lightweight (10 gm), and thin (<4 quarters thick)
  • Less embarrassment while dosing can lead to better adherence1
soft, flexible canula

Injection-Free Dosing

  • Fewer injections
    • 1 Patch = 9 mealtime injections = ~90 fewer injections / month
  • Less pain
    • 90% of users reported mealtime insulin painless with Patch1

The 3-day Patch holds up to 200 units of fast-acting insulin administered in 2-unit increments.

CeQur Simplicity Is Designed For Safety

2-button safety mechanism

2-Button Safety Mechanism

Ensures that dosing occurs only when intended—designed to prevent accidental dosing5

adhesive designed patch

Adhesive Patch

Designed to keep the Patch on skin for up to 3 days

button lock to notify

Buttons Lock To Notify

Stay in “squeezed” position when Patch is empty or cannula is occluded5

water resistant


To a depth of 1 meter for up to 30 minutes

audibe tactile click

Tactile & Audible Feedback

Indicates 2-unit delivery5


Use Of CeQur Simplicity Clinically Shown To
Improve Glycemic Control

Time in Range - Baseline
Time in Range - 24 Weeks

After 24 Weeks With CeQur Simplicity,
Users increased time-in-range (TIR) by 50%.2

The International consensus on time-in-range defines clinical target for TIR ≥70%, which is evidenced to be equivalent to an A1C of ≤7%.6

With Use Of CeQur Simplicity
A1C Target Goals Were Achieved1

A1C Target Goals Achieved

Clinical Outcome Study Findings.1 Mean A1C was reduced to target goal by Week 24.

Results were comparable to pens. Consistent A1C <7% supports HEDIS Comprehensive Diabetes Care measure.

man smiling

Users Prefer CeQur Simplicity

88% better follow their insulin regimen

said that they follow their insulin regimen better with the Patch3

86% satisfied with Patch

were satisfied with the Patch3

76% asked to be switched

asked to be switched from pen or syringe7

72% prefer patch over pens

preferred the Patch over pens1

CeQur Simplicity Encourages Adherence

Many people using the Patch said that they dosed in instances where they probably wouldn’t have dosed with a pen or syringe, and stated that they are likely to dose more often across meals, snacks, and correction boluses.3

CeQur Simplicity Features

CeQur Simplicity Features

*Labeled for use with Humalog® U-100 and NovoLog® U-100. Insulin sold separately.

  1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B on behalf of the Calibra Study Group. 2019. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with and Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.
  2. Johnson ML, Dreon DM, Levy BL, Richter S, Mullen D, Bergenstal R. 2018. Comparing Patch vs. Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles. Diabetes 2018 Jul; 67(Supplement 1)
  3. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association’s 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA.
  4. Peyrot M, Dreon D, Zraick V, Cross B, Tan MH. 2018. Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch. Diabetes Therapy. 9(1):297–307.
  5. Dreon D, Hannon T, Cross B, Carter B, Mercer N, Nguyen J, Tran A , Melendez P, Morales N, Nelson J, Tan M. 2018. Laboratory and Benchtop Performance of a Mealtime Insulin-Delivery System. Journal of Diabetes Science and Technology. 12(4):817-827.
  6. Battelino T, Danne T, Bergenstal R, Amiel S, Beck R, Biester T, Bosi E, Buckingham B, Cefalu W, Close K, Cobelli C, Dassau E, DeVries J, Donaghue K, Dovc K, Doyle F, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch I, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, LevineB, Mayorov A, Mathieu C, Murphy H, Nimri R, Nørgaard K, Parkin C, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer S, Phillip M. 2019. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care Aug 2019, 42 (8) 1593-1603
  7. Bohannon N, Bergenstal R, Cuddihy R, Kruger D, List S, Massaro E, Molich M, Raskin P, Remtema H, Strowig S, Whitehouse F, Brunelle R, Dreon D, Tan M. 2011. Comparison of a Novel Insulin Bolus-Patch with Pen/Syringe Injection to Deliver Mealtime Insulin for Efficacy, Preference, and Quality of Life in Adults with Diabetes: A Randomized, Crossover, Multicenter Study. Diabetes Technology & Therapeutics. 13(10):1031-1037.

Humalog® is a registered trademark of Eli Lilly and Company. NovoLog® is a registered trademark of Novo Nordisk A/S.